Monoclonal antibody "gold rush"

Current Medicinal Chemistry

Volumn 14, Issue 18, 2007, Pages 1978-1987

  Maggon, Krishan ^a  

^a Pharmaceutical Biotechnology RandD Advisor   (Switzerland)

Author keywords

And success factors; Blockbuster monoclonal; Gold Rush; Market data; Monoclonal antibodies; R D paradigm shift; Sales

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ARCITUMOMAB TC 99M; BASILIXIMAB; BEVACIZUMAB; CAPROMAB PENDETIDE IN 111; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; EFALIZUMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; MYCOGRAB; MYOSIN ANTIBODY IN 111; NATALIZUMAB; OKT 3; OMALIZUMAB; ORTHOCLONE; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VECTIBIX; ZENAPEX;

ALLERGIC ASTHMA; ANTIGEN BINDING; B CELL LEUKEMIA; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOGENICITY; KIDNEY GRAFT REJECTION; LUNG CANCER; MULTIPLE SCLEROSIS; PROSTATE CANCER; PSORIASIS; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS; ARTHRITIS; BIOPHARMACEUTICS; DRUG TOXICITY; HUMANS; NEOPLASMS;

EID: 34547696982     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986707781368504     Document Type: Review

References (63)

1. Meyers R. A. (Eds). Immunology: from cell biology to disease. Wiley: New York, 2007.
2. Kuby, J.; Kindt, T. J.; Osborne, B. A.; Goldsby R. A. Eds. Immunology. W. H. Freeman: London, 2006.
3. Roitt, I. M.; Martin S. J.; Delves P. J.; Burton D. Essential Immunology. Blackwell: London, 2006.
4. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov I.N.; Bourne, P.E. Nucleic Acids Res., 2000, 28, 235.
5. Berman, H.M.; Henrick, K.; Nakamura. H. Nat. Struct. Biol., 2003, 10, 980.
6. Hale, G. Adv. Drug Del. Rev., 2006, 58, 633.
7. Presta, L. G. Adv. Drug Del. Rev., 2006, 58, 640.
8. Wark, K. L.; Hudson, P. J. Adv. Drug Del. Rev., 2006, 58, 657.
9. Birch J. R.; Racher A. J. Adv. Drug Del. Rev., 2006, 58, 671.
10. Kozlowski S.; Swann P. Adv. Drug Del. Rev., 2006, 58, 707.
11. Farid, S. S. J. Chromatogr. B., 2007, 848, 8.
12. Boi, C. J. Chromatog. B., 2007, 848, 19.
13. Flatman, S.; Alam, I.; Gerard J.; Mussa, N. J. Chromatogr. B., 2007, 848, 79.
14. Daugherty, A. L.; Mrsny, R. J. Adv. Drug Del. Rev., 2006, 58, 686.
15. Maggon, K. In Handbook of Pharmaceutical Biotechnology. Gad, S. C. Ed.; Wiley: New York, 2007 In Press (June 2007).
16. Maggon, K. www.medicineandbiotech.com. e-Published, March 1st, 2007.
17. Bain & Company Report. Has the pharmaceutical blockbuster model gone bust. 2003. www.bain.com
18. Maggon, K. Pharmaceut. Exec., 2003, 23, 60.
19. Maggon, K. Drug Discov. Today, 2005, 10, 738.
20. Maggon, K. www.medicineandbiotech.com. e-Published, Feb 1st, 2007.
21. IMS Top Line Global Industry Data 2006. www.imshealth.com, http://www.ims-global.com/insight/insight.htm
22. Ernst & Young. Global Biotech Report 2006. www.ey.com
23. Pavlou, A. K.; Belsey, M. J. Commerc. Biotechnol., 2004, 11, 80.
24. Pavlou, A.K. J. Commerc. Biotechnol., 2004, 10, 273.
25. Reichert, J. M.; Rosenweig, C. J.; Faden, L. B.; Pavlou, A.K. Nat. Biotechnol., 2005, 23, 1073.
26. Pavlou, A. K.; Reichert, J. M. Nat. Biotechnol., 2004, 22, 1513.
27. Maggon, K. Express Pharma Pulse, February 5, 2004. www.expresspharmapulse.com/20040205/editorial02.shtml.
28. Maggon, K. Express Pharma Pulse, April 28, 2005. www.expresspharmapulse.com/20050428/edit02.shtml.
29. Evans, D.; Das, R. Monoclonal Antibodies: evolving into a $30 billion market. Datamonitor Report, 2005.
30. Bains, W. Drug Discov. World, 2006, 7, 28.
31. Haurum, J. S. Drug Discov. Today, 2006, 11, 655.
32. Moreland, L.; Bate, G.; Kirkpatrick, P. Nat. Rev., 2006, 5, 185.
33. Sesin, C. A.; Bingham, C. O. Semin. Arthrit. Rheum., 2005, 35, 185.
34. Miossec, P. Drug Discov. Today Dis. Mechan., 2005, 2, 327.
35. Liossis, S. N.C.; Tsokos, G. C. J. Allergy Clin. Immunol., 2005. 116, 721.
36. Chowdhury, P. S.; Wu, H. Humanized Antibodies Applications, 2005, 36, 11.
37. Reichert, J. M.; Pavlou, A. K. Nat. Rev., 2004, 3, 383.
38. Pavlou, A. K.; Belsey, M. J. Eur. J. Pharmaceut. Biopharmaceut., 2005, 59, 389.
39. Glennie, M.J.; van de Winkel, J.G.J. Drug Discov. Today, 2003, 8, 503.
40. Binyamin, L.; Hossein, B. H.; Weiner, L. M. Update Cancer Therapeut., 2006, 1, 147.
41. Tabrizi, M. A.; Tseng, C. M. L.; Roskos, L. K. Drug Discov. Today, 2006, 11, 81.
42. Waldmann, T. A.; Morris, J. C. Adv. Immunol., 2006, 90, 83.
43. Cartron, G.; Blasco, H.; Paintaud, G.; Watier, H.; Le Guellec, C. Crit. Rev. Oncol. Hematol., 2007, 62, 43.
44. Dassonville, O.; Bozec, A.; Fischel, J. L.; Milano, G. Crit. Rev. Oncol. Hematol., 2007, 62, 53.
45. Dutta, P. R.; Maity, A. Cancer Lett., 2007 In Press, Corrected Proof, Available online 28 March 2007.
46. Scannes, L.; Branca, M. A. Pharmaweek, 2006, 1. www.pharmaweek. com/Exclusive_Content/2_23%20test.asp.
47. Baker, M. Nat. Biotechnol., 2005, 23, 1065.
48. Steiner, U. Bayer Presentation. Conference on Plant Made Pharmaceuticals. Montreal, Canada. January 30-Feb 2, 2005. archives.cpmp2005.org/maintemplate.aspx?lang=en
49. Roche is driving the monoclonal antibody revolution. Pharmaceutical Business Review Online, 2006. www.pharmaceutical-business-review.com.
50. Hopkins, M. Nature, 2006, 440, 855.
51. Academy of Medical Science, London. Testing antibody therapies: position paper 2006. www.acmedsci.ac.uk.
52. Luby, M. Pharmaceut. Exec., 2006, 26, 118.
53. Villadsen, L.S.; Skov, L.; Dam, T. N.; Dagnaes-Hansen, F.; Rygaard, J.; Schuurman, J.; Parren, P.W.H.I.; van de Winkel, J. G. J.; Baadsgaard. O. Arch. Dermatol. Res., 2007, 298, 449.
54. Lammerts van Bueren, J.J.; Bleeker, W.K.; Bogh, H.O.; Houtkamp, M.; Schuurman, J.; van de Winkel, J.G.J.; Parren, P.W.H.I. Cancer Res., 2006, 66, 7630.
55. Bevaart, L.; Jansen, M.J.H.; van Vugt, M.J.; Verbeek, J.S.; Leusen, J.H.W.; van de Winkel, J.G.J. Cancer Res., 2006, 66, 1261.
56. Waldmann, T.A. Arthrit. Rheumat., 2005, 52, 2585.
57. Demonty, G.; Bernard-Marty, C.; Puglisi, F.; Mancini, I.; Piccart, M. Eur. J. Cancer, 2007, 43, 497.
58. Furst, D. E.; Wallis, R.; Broder, M.; Beenhouwer, D.O. Semin. Arthrit. Rheumat., 2006, 36, 159.
59. Nowak, D. Respir. Med., 2007, 100, 1907.
60. Loisel, L.; Ohresser, M.; Pallardy, M.; Daydé, D.; Berthou, C.; Cartron, G.; Watier, H. Crit. Rev. Oncol. Hematol., 2007, 62, 34.
61. Allegretti, M.; Moricini, A.; Beccari, A. R.; Di Bitondo, R.; Bizzarri, C.; Bertini, R.; Colotta, F. Curr. Med. Chem., 2005, 12, 217.
62. Maggon, K.; Barik, S. Rev. Mol. Virol., 2004, 14, 149.
63. Moore, M. L; Peebles, R. T. Pharmacol. Ther., 2006, 112, 405.